KEGG ID: 03320
KEGG Diagram for PPAR signaling pathway
There are 68 IPI Records from this pathway found in Rattus norvegicus.
Location of PPAR signaling pathway proteins on Rat Genome
| IPI Record | Position |
|---|---|
| 1: Acaa1 | 8:124305110-124313914 |
| 2: Acadl | 9:65613130-65651775 |
| 3: Acadm | 2:251866645-251890729 |
| 4: Acox1 | 10:106280444-106304660 |
| 5: Acox2 | 15:18647103-18677855 |
| 6: Acox3 | 14:80769000-80809809 |
| 7: Acsl1 | 16:49036892-49081416 |
| 8: Acsl3 | 9:78083235-78106933 |
| 9: Acsl4 | X:36202358-36232162 |
| 10: Acsl5 | 1:261571863-261598237 |
| 11: Acsl6 | 10:39718739-39777776 |
| 12: Adipoq | 11:79907786-79921124 |
| 13: Angptl4 | 7:16261621-16267852 |
| 14: Apoa1 | :- |
| 15: Apoa2 | 13:87114734-87116372 |
| 16: Apoa5 | 8:49253293-49255775 |
| 17: Apoc3 | :- |
| 18: Aqp7 | 5:58433731-58447853 |
| 19: Cd36 | 4:13472534-13522337 |
| 20: Cpt1a | 1:205852746-205912969 |
| 21: Cpt1b | 7:127737129-127746179 |
| 22: Cpt2 | 5:129007685-129025501 |
| 23: Cyp27a1 | 9:74039087-74068647 |
| 24: Cyp4a1 | 5:135901624-135915753 |
| 25: Cyp4a10 | :- |
| 26: Cyp4a3 | 5:135767919-135772855 |
| 27: Cyp4a8 | :- |
| 28: Cyp7a1 | 5:19707159-19716856 |
| 29: Cyp8b1 | 8:127018908-127020878 |
| 30: Dbi | :- |
| 31: Ehhadh | 11:81474172-81507660 |
| 32: Fabp1 | 4:104412205-104415981 |
| 33: Fabp2 | 2:219591502-219605097 |
| 34: Fabp3 | 5:149340536-149347265 |
| 35: Fabp4 | 2:93536110-93540773 |
| 36: Fabp5 | :- |
| 37: Fabp6 | 10:28694773-28699448 |
| 38: Fabp7 | 20:36812599-36816205 |
| 39: Fads2 | 1:212512807-212542623 |
| 40: Gyk | X:72421134-72493296 |
| 41: Hmgcs2 | 2:193128730-193143109 |
| 42: Ilk | 1:163481299-163487550 |
| 43: Lpl | 16:22532515-22556892 |
| 44: Me1 | 8:91841160-91955917 |
| 45: Mmp1a_predicted | 8:4333815-4353725 |
| 46: Nr1h3 | 3:75542181-75552096 |
| 47: Oldlr1 | 4:166747228-166769340 |
| 48: Pck1 | 3:164012410-164018359 |
| 49: Pck2_predicted | 15:33661629-33680492 |
| 50: Pdpk1 | 10:13329849-13362023 |
| 51: Plin | 1:135497431-135509926 |
| 52: Pltp_predicted | 3:155871842-155890270 |
| 53: Ppara | 7:123729774-123807090 |
| 54: Ppard | 20:6479092-6543024 |
| 55: Pparg | 4:151492110-151617338 |
| 56: RGD1562373_predicted | 8:124110412-124118925 |
| 57: Rxra | 3:6666298-6689224 |
| 58: Rxrb | 20:4954334-4960880 |
| 59: Rxrg | 13:83256823-83298724 |
| 60: Scd1 | 1:249458699-249471514 |
| 61: Scd2 | 1:249358105-249371164 |
| 62: Scp2 | :- |
| 63: Slc27a1 | 16:18769909-18786990 |
| 64: Slc27a2 | 3:114073362-114113963 |
| 65: Slc27a4 | 3:8790158-8802884 |
| 66: Slc27a6_predicted | 18:54351692-54411779 |
| 67: Ubc | 12:32333187-32337945 |
| 68: Ucp1 | 19:26527548-26535621 |
There are 68 IPI Records from this pathway found in Mus musculus.
Location of PPAR signaling pathway proteins on Mouse Genome
| IPI Record | Position |
|---|---|
| 1: Acadl | 1:66764061-66796457 |
| 2: Acadm | 3:153859745-153881818 |
| 3: Acox1 | 11:115987978-116015135 |
| 4: Acox2 | 14:7019267-7052692 |
| 5: Acox3 | 5:35899921-35930662 |
| 6: Acsl1 | 8:47969859-48034867 |
| 7: Acsl3 | 1:78536898-78586015 |
| 8: Acsl4 | X:137564361-137636903 |
| 9: Acsl5 | 19:55306619-55350970 |
| 10: Acsl6 | 11:54147221-54204962 |
| 11: Adipoq | 16:23061870-23073302 |
| 12: Angptl4 | 17:33380630-33388455 |
| 13: Apoa1 | 9:45979952-45981463 |
| 14: Apoa2 | 1:173061764-173063045 |
| 15: Apoa5 | 9:46020073-46022914 |
| 16: Apoc3 | 9:45984046-45986292 |
| 17: Aqp7 | 4:41221917-41236641 |
| 18: Cd36 | 5:17297546-17340718 |
| 19: Cpt1a | 19:3323320-3385732 |
| 20: Cpt1b | 15:89244388-89253629 |
| 21: Cpt1c | 7:44826526-44842856 |
| 22: Cpt2 | 4:107401912-107421466 |
| 23: Cyp27a1 | 1:74646781-74671097 |
| 24: Cyp4a10 | 4:115016219-115031581 |
| 25: Cyp4a12b | 4:114796978-114936971 |
| 26: Cyp4a14 | 4:114984077-114994064 |
| 27: Cyp7a1 | 4:6192759-6202778 |
| 28: Cyp8b1 | 9:121763460-121764962 |
| 29: Dbi | 1:121940826-121948625 |
| 30: Ehhadh | 16:21675270-21701786 |
| 31: Fabp1 | 6:71129471-71134602 |
| 32: Fabp2 | 3:122887398-122891525 |
| 33: Fabp3 | 4:129811044-129817762 |
| 34: Fabp4 | 3:10186879-10191108 |
| 35: Fabp5 | 3:9995121-9999139 |
| 36: Fabp6 | 11:43439535-43444934 |
| 37: Fabp7 | 10:57473338-57476865 |
| 38: Fads2 | 19:10129825-10168474 |
| 39: Gk2 | 5:97695615-97697279 |
| 40: Gyk | X:81958952-82029222 |
| 41: Hmgcs2 | 3:98365840-98396137 |
| 42: Ilk | 7:105610473-105616745 |
| 43: IPI00378311 | 18:7581520-7581915 |
| 44: IPI00755916 | 5:125675482-125679691 |
| 45: Lpl | 8:71809547-71836437 |
| 46: Me1 | 9:86378094-86492925 |
| 47: Mmp1a | 9:7464141-7476856 |
| 48: Mmp1b | 9:7368239-7387993 |
| 49: Nr1h3 | 2:90984949-90995955 |
| 50: Olr1 | 6:129453359-129472800 |
| 51: Pck1 | 2:172796012-172802209 |
| 52: Pck2 | 14:54494337-54504088 |
| 53: Pdpk1 | 17:23803292-23869207 |
| 54: Plin | 7:79594677-79606283 |
| 55: Pltp | 2:164530723-164548913 |
| 56: Ppara | 15:85605326-85629024 |
| 57: Ppard | 17:27960392-28029058 |
| 58: Pparg | 6:115387685-115456020 |
| 59: Rxra | 2:27499210-27585328 |
| 60: Rxrb | 17:33642306-33648853 |
| 61: Rxrg | 1:169435059-169476298 |
| 62: Scd1 | 19:44447766-44460864 |
| 63: Scd2 | 19:44347399-44360171 |
| 64: Scd3 | 19:44256599-44297327 |
| 65: Scp2 | 4:107541771-107616433 |
| 66: Slc27a1 | 8:74497916-74515697 |
| 67: Slc27a2 | 2:126244482-126279682 |
| 68: Slc27a4 | 2:29624689-29639531 |
| 69: Slc27a5 | 7:11888525-11898329 |
| 70: Slc27a6 | 18:58681609-58738238 |
| 71: Sorbs1 | 19:40348360-40451928 |
| 72: Ucp1 | 8:86180457-86188557 |
There are 68 IPI Records from this pathway found in Homo sapiens.
Location of PPAR signaling pathway proteins on Human Genome
| IPI Record | Position |
|---|---|
| 1: ACAA1 | 3:38139223-38153703 |
| 2: ACADL | 2:210760963-210798405 |
| 3: ACADM | 1:75962624-76001952 |
| 4: ACOX1 | 17:71453260-71487039 |
| 5: ACOX2 | 3:58465906-58497956 |
| 6: ACOX3 | 4:8419265-8493338 |
| 7: ACSL1 | 4:185913744-185984209 |
| 8: ACSL3 | 2:223433976-223516360 |
| 9: ACSL4 | X:108771220-108863277 |
| 10: ACSL5 | 10:114123766-114178128 |
| 11: ACSL6 | 5:131170735-131375678 |
| 12: ADIPOQ | 3:188043157-188058944 |
| 13: ANGPTL4 | 19:8335011-8345257 |
| 14: APOA1 | 11:116211677-116213876 |
| 15: APOA2 | 1:159458706-159460042 |
| 16: APOA5 | 11:116165293-116167821 |
| 17: APOC3 | 11:116205818-116208998 |
| 18: AQP7 | 9:33374948-33392517 |
| 19: CD36 | 7:80069459-80141668 |
| 20: CPT1A | 11:68278666-68365960 |
| 21: CPT1B | 22:49354156-49363862 |
| 22: CPT1C | 19:54886219-54908800 |
| 23: CPT2 | 1:53434689-53626815 |
| 24: CYP27A1 | 2:219354745-219388254 |
| 25: CYP4A11 | 1:47167493-47180004 |
| 26: CYP4A22 | 1:47375433-47387940 |
| 27: CYP7A1 | 8:59565292-59575275 |
| 28: CYP8B1 | 3:42890807-42892312 |
| 29: DBI | 2:119841055-119846586 |
| 30: EHHADH | 3:186391108-186454531 |
| 31: FABP1 | 2:88203625-88208693 |
| 32: FABP2 | 4:120457854-120462766 |
| 33: FABP3 | 1:31610687-31618510 |
| 34: FABP4 | 8:82553484-82558023 |
| 35: FABP5 | 8:82355326-82359561 |
| 36: FABP6 | 5:159573319-159598307 |
| 37: FABP7 | 6:123142319-123146918 |
| 38: FADS2 | 11:61340325-61391401 |
| 39: GK | X:30581397-30658646 |
| 40: GK2 | 4:80546717-80548378 |
| 41: HMGCS2 | 1:120092142-120113040 |
| 42: ILK | 11:6581540-6588673 |
| 43: LOC387934 | :- |
| 44: LOC642956 | :- |
| 45: LPL | 8:19841232-19867912 |
| 46: ME1 | 6:83976827-84197509 |
| 47: MMP1 | 11:102165861-102174099 |
| 48: NR1H3 | 11:47227083-47246972 |
| 49: OLR1 | 12:10202171-10216004 |
| 50: PCK1 | 20:55569543-55574922 |
| 51: PCK2 | 14:23633323-23643179 |
| 52: PDPK1 | 16:2527971-2593189 |
| 53: PLIN | 15:88008607-88023595 |
| 54: PLTP | 20:43960719-43974169 |
| 55: PPARA | 22:44925163-45018317 |
| 56: PPARD | 6:35418320-35503933 |
| 57: PPARG | 3:12304359-12450840 |
| 58: RXRA | 9:136358137-136472250 |
| 59: RXRB | 6:33269343-33276417 |
| 60: RXRG | 1:163636778-163681057 |
| 61: SCD | 10:102096762-102114577 |
| 62: SCP2 | 1:53165536-53289870 |
| 63: SLC27A1 | 19:17442350-17477977 |
| 64: SLC27A2 | 15:48261716-48315873 |
| 65: SLC27A4 | 9:130142661-130163322 |
| 66: SLC27A5 | 19:63701516-63715244 |
| 67: SLC27A6 | 5:128328720-128396887 |
| 68: SORBS1 | 10:97061520-97311161 |
| 69: UBC | 17:16225092-16226779 |
| 70: UCP1 | 4:141700500-141709457 |
BMC Genomics. 2009 Nov 19; 10(1): 542
Moyes KM, Drackley JK, Morin DE, Bionaz M, Rodriguez-Zas SL, Everts RE, Lewin HA, Loor JJ
ABSTRACT: BACKGROUND: Information generated via microarrays might uncover interactions between the mammary gland and Streptococcus uberis (S. uberis) that could help identify control measures for the prevention and spread of S. uberis mastitis, as well as improve overall animal health and welfare, and decrease economic losses to dairy farmers. The main objective of this study was to determine the most affected gene networks and pathways in mammary tissue in response to an intramammary infection (IMI) with S. uberis and relate these with other physiological measurements associated with immune and/or metabolic responses to mastitis challenge with S. uberis O140J. RESULTS: Streptococcus uberis IMI resulted in 2,102 (1,939 annotated) differentially expressed genes (DEG; YES versus NO). Within this set of DEG, we uncovered 20 significantly enriched canonical pathways (with 20 to 61 genes each), the majority of which were signaling pathways. Among the most inhibited were LXR/RXR signaling and PPARalpha/RXRalpha signaling. pathways activated by IMI were IL-10 signaling and IL-6 signaling which likely reflected counter mechanisms of mammary tissue to respond to infection. Of the 2,102 DEG, 1,082 were up-regulated during IMI and were primarily involved with the immune response, e.g., IL6, TNF, IL8, IL10, SELL, LYZ, and SAA3. Genes down-regulated (1,020) included those associated with milk fat synthesis, e.g., LPIN1, LPL, CD36, and BTN1A1. Network analysis of DEG indicated that TNF had positive relationships with genes involved with immune system function (e.g., CD14, IL8, IL1B, and TLR2) and negative relationships with genes involved with lipid metabolism (e.g., GPAM, SCD, FABP4, CD36, and LPL) and antioxidant activity (SOD1). CONCLUSIONS: Results provided novel information into the early signaling and metabolic pathways in mammary tissue that are associated with the innate immune response to S. uberis infection. Our study indicated that IMI challenge with S. uberis (strain O140J) elicited a strong transcriptomic response, leading to potent activation of pro-inflammatory pathways that were associated with a marked inhibition of lipid synthesis, stress-activated kinase signaling cascades, and PPAR signaling (most likely PPARgamma). This latter effect may provide a mechanistic explanation for the inverse relationship between immune response and milk fat synthesis.
Cell Signal. 2009 Nov 13;
Mo C, Chearwae W, Bright JJ
Embryonic stem (ES) cells are genetically normal, pluripotent cells, capable of self-renewal and multi-lineage differentiation. Leukemia inhibitory factor (LIF) is a growth factor that can maintain the pluripotency of mouse ES cells in culture. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor transcription factors that regulate growth and differentiation of many cell types. We have shown earlier that 15-Deoxy-(12,14)-Prostaglandin J2 (15d-PGJ2), a natural ligand for PPARgamma, inhibits LIF-induced proliferation of mouse ES cells in culture. In this study we demonstrate that the PPARgamma antagonist Bisphenol A diglycidyl ether (BADGE) and 2-Chloro-5-nitro-N-(4-pyridyl)benzamide (T0070907) reverse the inhibition of ES cell proliferation by PPARgamma agonists. Stable transfection of ES cells with a dominant negative PPARgamma1 mutant also reduced the inhibition of proliferation by PPARgamma agonists. While 15d-PGJ2 and ciglitazone induced growth-arrest in ES cells by blocking LIF signaling, PPARgamma antagonists and dominant negative PPARgamma1 mutant reversed proliferation by restoring LIF-induced Tyk2-Stat3 signaling. These results suggest that PPARgamma regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway.
Toxicology. 2009 Oct 28;
Fang X, Feng Y, Wang J, Dai J
Perfluoroalkyl acid (PFAA)-induced apoptosis has been reported in many cell types. However, minimal information on its mode of action is available. This study explored the possible involvement of apoptotic signaling pathways in a nine-carbon-chain length PFAA-perfluorononanoic acid (PFNA)-induced splenocyte apoptosis. After a 14-day exposure to PFNA, rat spleens showed dose-dependent levels of apoptosis. The production of pro-inflammatory and anti-inflammatory cytokines was significantly increased and decreased, respectively. However, protein levels of tumor necrosis factor receptor 1 (TNFR1), fas-associated protein with death domain (FADD), caspase 8 and caspase 3, which are involved in inflammation-related and caspase-dependent apoptosis, were discordant. Peroxisome proliferator-activated receptors alpha (PPARalpha) and PPARgamma genes expression was up-regulated in rats treated with 3 or 5mg/kg/day of PFNA, and the level of hydrogen peroxide (H(2)O(2)) increased concurrently in rats treated with the highest dose. Moreover, superoxide dismutase (SOD) activity and Bcl-2 protein levels were dramatically decreased in spleens after treatment with 3 and 5mg/kg/day of PFNA. However, protein levels of Bax were unchanged. Apoptosis-inducing factor (AIF), an initiator of caspase-independent apoptosis, was significantly increased in all PFNA-dosed rats. Thus, oxidative stress and the activation of a caspase-independent apoptotic signaling pathway contributed to PFNA-induced apoptosis in rat splenocytes.
Signal Transduction via Cannabinoid Receptors.
CNS Neurol Disord Drug Targets. 2009 Oct 19;
Dalton GD, Bass CE, Van Horn C, Howlett AC
The endocannabinoids anandamide and 2-arachidonoylglycerol are lipid mediators that signal via CB1 and CB2 cannabinoid receptors and Gi/o-proteins to inhibit adenylyl cyclase and stimulate mitogen-activated protein kinase. In the brain, CB1 receptors interact with opioid receptors in close proximity, and these receptors may share G-proteins and effector systems. In the striatum, CB1 receptors function in coordination with D1 and D2 dopamine receptors, and combined stimulation of CB1-D2 receptor heteromeric complexes promotes a unique interaction to stimulate cAMP production. CB1 receptors also trigger growth factor receptor signaling cascades in cells by engaging in cross-talk or interreceptor signal transmission with the receptor tyrosine kinase (RTK) family. Mechanisms for CB1 receptor-RTK transactivation can include stimulation of signal transduction pathways regulated by second messengers such as phospholipase C, metalloprotease cleavage of membrane-bound precursor proteins such as epidermal growth factor which activate RTKs, RTK autophosphorylation, and recruitment of non-receptor tyrosine kinases. CB1 and CB2 receptors are expressed in peripheral tissues including liver and adipose tissue, and are induced in pathological conditions. Novel signal transduction resulting from endocannabinoid regulation of AMP-regulated kinase and peroxisome proliferator-activated receptors have been discovered from studies of hepatocytes and adipocytes. It can be predicted that drug discovery of the future will be based upon these novel signal transduction mechanisms for endocannabinoid mediators.
Am J Physiol Endocrinol Metab. 2009 Oct 6;
Wang M, Wang JJ, Li J, Park K, Qian X, Ma JX, Zhang SX
Aims. We previously reported that circulating levels of pigment epithelium-derived factor (PEDF), a newly identified adipokine, are increased in patients with type 2 diabetes, correlating with body mass index. However, the role of PEDF in adipogenesis remains elusive. In the present study, we have investigated the effects and mechanisms of PEDF on adipocyte differentiation in 3T3-L1 preadipocytes. Methods. Differentiation of 3T3-L1 preadipocytes was induced in the presence or absence of human recombinant PEDF protein. The effects of PEDF on adipogenic gene expression, mitotic clonal expansion (MCE), and MAPK activation were investigated. Results. Physiological concentrations of human PEDF protein inhibited adipocyte differentiation, evidenced by decreased lipid accumulation, down-regulation of adipocyte markers, and inhibition of master adipogenic transcription factors, such as C/EBP-alpha and PPAR-gamma. The anti-adipogenic effects of PEDF were observed only when PEDF was added to the cells at day 0, but not at day 3 during differentiation, suggesting that PEDF targets some early adipogenic events. Similarly, over-expression of PEDF by adenovirus attenuated adipocyte differentiation. Further studies revealed that PEDF, or U0126, a specific MAPK/ERK inhibitor, sequentially inhibited the early activation of ERK and MCE. Moreover, PEDF attenuated expression and the phosphorylation of C/EBP-beta at Thr188, an essential step for transcriptional activation of C/EBP-beta. In addition, PEDF expression was significantly decreased in the first 24 h during adipocyte differentiation, suggesting that down-regulation of PEDF may be essential for the initiation of MCE and adipogenesis. Conclusions. PEDF inhibits adipogenesis in 3T3-L1 preadipocytes, partially due to inhibition of the MAPK/ERK signaling pathway and MCE.
Int J Mol Med. 2009 Nov; 24(5): 623-32
Liu JJ, Guo YW, Fang ZG, Si XN, Wu XY, Liu PQ, Lin DJ, Xiao RZ, Xu Y, Wang CZ, Li XD, He Y, Huang RW
In the present study we investigated the in vitro apoptosis inducing effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand ciglitazone (CGZ) on acute promyelocytic leukemia (APL) NB4 cells and its mechanisms of action. The results revealed that CGZ (10-50 micromol/l) inhibited the growth of leukemia NB4 cells and caused apoptosis in a time- and dose-dependent manner. Apoptosis was observed clearly by flow cytometry (FCM) and DNA fragmentation analysis. After treatment by CGZ for 48 h, the percentage of disruption of mitochondrial membrane potential (Deltapsim) was increased in a dose-dependent manner. Western blotting demonstrated the cleavage of caspase-3 zymogen protein and a time-dependent cleavage of poly (ADP-ribose) polymerase (PARP). The results also demonstrated that PPAR-gamma expression was increased concomitantly when apoptosis occurred, and that CGZ-induced apoptosis was inhibited by the PPAR-gamma antagonist GW9662, suggesting a PPAR-gamma dependent signaling pathway in CZG-induced cell death. Moreover, CGZ treatment remarkably downregulated the expression of the X-linked inhibitor of apoptosis protein (XIAP), which was inhibited by GW9662. Of note, a small-molecule XIAP antagonist (1396-12) mimicked the effect of CGZ-induced apoptosis via activation of caspase-3, 7 and 9. The apoptosis-inducing effects by CGZ on fresh APL cells were also found to be remarkable by using FCM and Wright's staining observation. Taken together, our results suggest that downregulation of XIAP and activation of capase-3 play an important role in mediating the PPAR-gamma-dependent cell death induced by CGZ in APL cells. These data provide a novel insight into potential therapeutic strategies for treatment of leukemia.
Leuk Res. 2009 Sep 26;
Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT
Targeting of signal transduction pathways and transcriptional regulation represents an attractive approach for less toxic anti-leukaemic therapy. We combined protein kinase A (PKA) activation with a pan-peroxisome proliferator-activated receptor (PPAR) activator tetradecylthioacetic acid, resulting in synergistic decrease in viability of AML cell lines. PKA isoform II activation appeared to be involved in inhibition of proliferation but not induction of apoptosis in HL-60 cells. Inhibition of CREB function protected against this anti-leukaemic effect with higher efficiency than enforced Bcl-2 expression. Preclinical studies employing the rat AML model Brown Norwegian Myeloid Leukaemia also indicated anti-leukaemic activity of the combination therapy in vivo. In conclusion, combined PKA and pan-PPAR activation should be explored further to determine its therapeutic potential.
Atherosclerosis. 2009 Sep 6;
Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B
OBJECTIVE: Serum paraoxonase-1 (PON1) expression is regulated by polyphenols, shown to activate the peroxisome proliferator-activated receptor gamma (PPARgamma). Pomegranate juice (PJ) is a polyphenol-rich fruit. Because promoter sequence of PON1 gene indicates that it could be regulated by nuclear receptors, we investigated the effect of PJ polyphenols on PON1 gene expression in HuH7 hepatocytes. METHODS AND RESULTS: PON1 protein or mRNA expression, determined by immunocytochemistry, or quantitative PCR, respectively, as well as PON1 gene promoter activation, was significantly increased in hepatocytes incubated with PJ or with its major polyphenols punicalagin, or gallic acid (GA). Ellagic acid (EA) elicited only modest stimulatory effect. Accordingly, PJ, punicalagin, GA, and less so EA, dose-dependently increased cell-associated and hepatocyte-secreted PON1 arylesterase activity. Functionally, the secreted PON1 exhibited biological activity by protecting LDL and HDL from oxidation. Finally, PJ polyphenols upregulated the hepatocyte PON1 expression, at least in part, via the intracellular signaling cascade PPARgamma-PKA-cAMP. CONCLUSIONS: This study shows for the first time that PJ polyphenols have a specific transcriptional role in hepatocyte PON1 expression upregulation, and its secretion to the medium. We conclude that the anti-atherogenic characteristics of PJ polyphenols are modulated, at least in part, via hepatocyte PON1 upregulation and its subsequent release to the medium.
Downregulation of protein tyrosine phosphatase PTP-BL represses adipogenesis.
Int J Biochem Cell Biol. 2009 Nov; 41(11): 2173-80
Glondu-Lassis M, Dromard M, Chavey C, Puech C, Fajas L, Hendriks W, Freiss G
The insulin/insulin-like growth factor 1 (IGF-1) signaling pathway is a major regulator of adipose tissue growth and differentiation. We recently demonstrated that human protein tyrosine phosphatase (PTP) L1, a large cytoplasmic phosphatase also known as PTP-BAS/PTPN13/PTP-1E, is a negative regulator of IGF-1R/IRS-1/Akt pathway in breast cancer cells. This triggered us to investigate the potential role of PTPL1 in adipogenesis. To evaluate the implication of PTP-BL, the mouse orthologue of PTPL1, in adipose tissue biology, we analyzed PTP-BL mRNA expression in adipose tissue in vivo and during proliferation and differentiation of 3T3-L1 pre-adipocytes. To elucidate the role of PTP-BL and of its catalytic activity during adipogenesis we use siRNA techniques in 3T3-L1 pre-adipocytes, and mouse embryonic fibroblasts that lack wildtype PTP-BL and instead express a variant without the PTP domain (Delta P/Delta P MEFs). Here we show that PTP-BL is strongly expressed in white adipose tissue and that PTP-BL transcript and protein levels increase during proliferation and differentiation of 3T3-L1 pre-adipocytes. Strikingly, knockdown of PTP-BL expression in 3T3-L1 adipocytes caused a dramatic decrease in adipogenic gene expression levels (PPAR gamma, aP2) and lipid accumulation but did not interfere with the insulin/Akt pathway. Delta P/Delta P MEFs differentiate into the adipogenic lineage as efficiently as wildtype MEFs. However, when expression of either PTP-BL or PTP-BL Delta P was inhibited a dramatic reduction in the number of MEF-derived adipocytes was observed. These findings demonstrate a key role for PTP-BL in 3T3-L1 and MEF-derived adipocyte differentiation that is independent of its enzymatic activity.
J Neurosci Res. 2009 Sep 22;
Chen SD, Lin TK, Yang DI, Lee SY, Shaw FZ, Liou CW, Chuang YC
Peroxisome proliferator-activated receptors gamma coactivator-1alpha (PGC-1alpha) may regulate the mitochondrial antioxidant defense system under many neuropathological settings. However, the exact role of PGC-1alpha in ischemic brain damage is still under debate. Based on an experimental model of transient global ischemia (TGI), this study evaluated the hypothesis that the activation of PGC-1alpha signaling pathway protects hippocampal CA1 neurons against delayed neuronal death after TGI. In Sprague-Dawley rats, significantly increased content of oxidized proteins in the hippocampal CA1 tissue was observed as early as 30 min after TGI, followed by augmentation of PGC-1alpha expression at 1 hr. Expression of uncoupling protein 2 (UCP2) and superoxide dismutases 2 (SOD2) in the hippocampal CA1 neurons was upregulated 4-48 hr after TGI. In addition, knock-down of PGC-1alpha expression by pretreatment with a specific antisense oligodeoxynucleotide in the hippocampal CA1 subfield downregulated the expression of UCP2 and SOD2 with resultant exacerbation of oxidative stress and augmentation of delayed neuronal cell death in the hippocampus after TGI. Overall, our results indicate that PGC-1alpha is induced by cerebral ischemia leading to upregulation of UCP2 and SOD2, thereby providing a neuroprotective effect against ischemic brain injury in the hippocampus by ameliorating oxidative stress. (c) 2009 Wiley-Liss, Inc.
Circ Res. 2009 Oct 23; 105(9): 886-96
Chan SH, Wu CA, Wu KL, Ho YH, Chang AY, Chan JY
RATIONALE: Mitochondrial uncoupling proteins (UCPs) belong to a superfamily of mitochondrial anion transporters that uncouple ATP synthesis from oxidative phosphorylation and mitigates mitochondrial reactive oxygen species production. OBJECTIVE: We assessed the hypothesis that UCP2 participates in central cardiovascular regulation by maintaining reactive oxygen species homeostasis in the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons that maintain vasomotor tone located. We also elucidated the molecular mechanisms that underlie transcriptional upregulation of UCP2 in response to oxidative stress in RVLM. METHODS AND RESULTS: In Sprague-Dawley rats, transcriptional upregulation of UCP2 in RVLM by rosiglitazone, an activator of its transcription factor peroxisome proliferator-activated receptor (PPAR)gamma, reduced mitochondrial hydrogen peroxide level in RVLM and systemic arterial pressure. Oxidative stress induced by microinjection of angiotensin II into RVLM augmented UCP2 mRNA or protein expression in RVLM, which was antagonized by comicroinjection of NADPH oxidase inhibitor (diphenyleneiodonium chloride), superoxide dismutase mimetic (tempol), or p38 mitogen-activated protein kinase inhibitor (SB203580) but not by extracellular signal-regulated kinase 1/2 inhibitor (U0126). Angiotensin II also induced phosphorylation of the PPARgamma coactivator, PPARgamma coactivator (PGC)-1alpha, and an increase in formation of PGC-1alpha/PPARgamma complexes in a p38 mitogen-activated protein kinase-dependent manner. Intracerebroventricular infusion of angiotensin II promoted an increase in mitochondrial hydrogen peroxide production in RVLM and chronic pressor response, which was potentiated by gene knockdown of UCP2 but blunted by rosiglitazone. CONCLUSIONS: These results suggest that transcriptional upregulation of mitochondrial UCP2 in response to an elevation in superoxide plays an active role in feedback regulation of reactive oxygen species production in RVLM and neurogenic hypertension associated with chronic oxidative stress.
Am J Physiol Endocrinol Metab. 2009 Sep 15;
Kadotani A, Tsuchiya Y, Hatakeyama H, Katagiri H, Kanzaki M
In skeletal muscle, saturated free fatty acids (FFAs) act as pro-inflammatory stimuli, and cyclooxygenase-2 (COX-2) is a pro-/anti-inflammatory enzyme, induced at sites of inflammation, which contributes to prostaglandin production. However, little is known about the regulation of COX-2 expression and its responses to FFAs in skeletal muscle. Herein, we examined the effects of saturated and unsaturated FFAs including a recently identified lipokine (lipid hormone derived from adipocytes), palmitoleate, on COX-2 expression in C2C12 myotubes as a skeletal muscle model. Exposure of myotubes to saturated FFAs (palmitate [16:0], stearate [18:0]), but not to unsaturated FFAs (palmitoleate [16:1], oleate [18:1], linoleate [18:2]), led to a slow-onset induction of COX-2 expression and subsequent prostaglandin E2 production via mechanisms involving the p38 MAPK and NF-kappaB, but not the PKC signaling cascades. Pharmacological modulation of mitochondrial oxidative function failed to interfere with COX-2 expression, suggesting the mitochondrial overload/excessive beta-oxidation contribution to this event to be minimal. On the contrary, unsaturated FFAs appeared to effectively antagonize palmitate-induced COX-2 expression with markedly different potencies (linoleate > oleate > palmitoleate), being highly associated with the suppressive profile of each unsaturated FFA towards palmitate-evoked intracellular signals including p38, JNK, Erk1/2 MAPKs and PKC as well as IkappaB degradation. In addition, our data suggest little involvement of PPAR in the protective actions of unsaturated FFAs against palmitate-induced COX-2 expression. No direct contribution of the increased COX-2 activity in generating palmitate-induced insulin resistance was detected, at least in terms of insulin-responsive Akt phosphorylation and GLUT4 translocation. Taken together, our data provide a novel insight into the molecular mechanisms responsible for the FFA-induced COX-2 expression in skeletal muscle, and raise the possibility that, in skeletal myocytes, COX-2 and its product prostaglandins may play an important role in the complex inflammation responses caused by elevated FFAs, for example, in the diabetic state. Key words: GLUT4, inflammation, signal transduction, lipokine.
Virology. 2009 Nov 10; 394(1): 130-42
Lyn RK, Kennedy DC, Sagan SM, Blais DR, Rouleau Y, Pegoraro AF, Xie XS, Stolow A, Pezacki JP
Here we have simultaneously characterized the influence of inhibitors of peroxisome proliferator-activated receptor alpha (PPARalpha) and the mevalonate pathway on hepatocyte lipid metabolism and the subcellular localization of hepatitis C virus (HCV) RNA using two-photon fluorescence (TPF) and coherent anti-Stokes Raman scattering (CARS) microscopy. Using this approach, we demonstrate that modulators of PPARalpha signaling rapidly cause the dispersion of HCV RNA from replication sites and simultaneously induce lipid storage and increases in lipid droplet size. We demonstrate that reductions in the levels of cholesterol resulting from inhibition of the mevalonate pathway upregulates triglyceride levels. We also show that the rate of dispersion of HCV RNA is very rapid when using a PPARalpha antagonist. This occurs with a faster rate to that of direct inhibition of 3-hydroxy-3-methyglutaryl CoA reductase (HMG-CoA reductase) using lovastatin in living cells, demonstrating the potential therapeutic value of modulating host cell pathways as part of a strategy to eliminate chronic HCV infection.
Cancer Cell. 2009 Sep 8; 16(3): 220-31
Shankaranarayanan P, Rossin A, Khanwalkar H, Alvarez S, Alvarez R, Jacobson A, Nebbioso A, de Lera AR, Altucci L, Gronemeyer H
Growth factor (GF) deprivation and/or blocking of cognate signaling can induce apoptosis and is the basis of several cancer treatment paradigms. We observed that RXR agonists (rexinoids) induce apoptosis of tumor cells when GF support is abrogated. This "rexinoid apoptosis" involves activation of both iNOS and eNOS by RXR-PPARgamma and results in production of apoptogenic NO. IGF/EGF-induced IGF receptor 1-mediated MAP kinase blocks rexinoid apoptosis by RXR phosphorylation. Combining rexinoids with the MAPK inhibitor U0126 induced apoptosis in human cancer cells in vitro and ex vivo and blocked xenograft growth in vivo. Our results suggest a regulatory mechanism in which GF signaling antagonizes RXR-PPARgamma-mediated default apoptosis to sustain cell life.
Arthritis Rheum. 2009 Sep; 60(9): 2822-9
Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A
OBJECTIVE: There is increasing evidence that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) plays an important role in controlling cell differentiation, and that PPARgamma ligands can modify inflammatory and fibrotic responses. The aim of the present study was to examine the role of PPARgamma in a mouse model of skin scleroderma, in which mice bearing a fibroblast-specific deletion of PPARgamma were used. METHODS: Cutaneous sclerosis was induced by subcutaneous injection of bleomycin, while untreated control groups were injected with phosphate buffered saline. Mice bearing a fibroblast-specific deletion of PPARgamma were investigated for changes in dermal thickness, inflammation, collagen content, and the number of alpha-smooth muscle actin-positive cells. The quantity of the collagen-specific amino acid hydroxyproline was also measured. In addition, the effect of PPARgamma deletion on transforming growth factor beta1 (TGFbeta1) signaling in the fibroblasts was investigated. RESULTS: Bleomycin treatment induced marked cutaneous thickening and fibrosis in all treated mice. Deletion of PPARgamma resulted in enhanced susceptibility to bleomycin-induced skin fibrosis, as indicated by increases in all measures of skin fibrosis and enhanced sensitivity of fibroblasts to TGFbeta1 in PPAR-deficient mice. CONCLUSION: These results indicate that PPARgamma suppresses fibrogenesis. Specific agonists of PPARgamma may therefore alleviate the extent of the development of cutaneous sclerosis.
Reprod Fertil Dev. 2009; 21(7): 909-22
Kowalewski MP, Dyson MT, Manna PR, Stocco DM
Peroxisome proliferator-activated receptor (PPAR) gamma belongs to the PPAR family of nuclear transcription factors whose ligands, such as eicosanoids, fatty acids and prostaglandins, are known to affect gonadal function. Although several of these enhance the expression of the steroidogenic acute regulatory protein (STAR) and steroid production, the role of PPARgamma in regulating STAR-mediated steroidogenesis remains unclear. In the present study, we used ciglitazone to selectively activate PPARgamma and examine its role in STAR-mediated steroidogenesis in immortalised KK1 mouse granulosa cells and MA-10 mouse Leydig tumour cells. Cotreatment with both dibutyryl-cAMP and ciglitazone revealed a dose-dependent, significant increase in progesterone synthesis, Star promoter activity, Star mRNA and STAR protein relative to either compound alone. The overexpression of PPARgamma further increased Star-promoter activity. The ciglitazone-induced activity of the Star-promoter appears to be mediated through the cAMP-response element half-sites located within its proximal 151 bp. Combined treatment with ciglitazone and dibutyryl-cAMP significantly increased the expression and activity of transcriptional pathways impacted by the activator protein-1 family member c-JUN. The present study demonstrates that ciglitazone and dibutyryl-cAMP synergistically enhance STAR expression in MA-10 and KK1 cells. Ciglitazone-activated PPARgamma appears to increase the sensitivity of Leydig and granulosa cells to cAMP stimulation, possibly via upregulation of c-JUN expression.
Circulation. 2009 Aug 25; 120(8): 687-98
Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB, Bernal-Mizrachi L, Bernal-Mizrachi C
BACKGROUND: Cardiovascular disease is the leading cause of death among those with diabetes mellitus. Vitamin D deficiency is associated with an increased risk of cardiovascular disease in this population. To determine the mechanism by which vitamin D deficiency mediates accelerated cardiovascular disease in patients with diabetes mellitus, we investigated the effects of active vitamin D on macrophage cholesterol deposition. METHODS AND RESULTS: We obtained macrophages from 76 obese, diabetic, hypertensive patients with vitamin D deficiency (25-hydroxyvitamin D <80 nmol/L; group A) and 4 control groups: obese, diabetic, hypertensive patients with normal vitamin D (group B; n=15); obese, nondiabetic, hypertensive patients with vitamin D deficiency (group C; n=25); and nonobese, nondiabetic, nonhypertensive patients with vitamin D deficiency (group D; n=10) or sufficiency (group E; n=10). Macrophages from the same patients in all groups were cultured in vitamin D-deficient or 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] -supplemented media and exposed to modified low-density lipoprotein cholesterol. 1,25(OH)(2)D(3) suppressed foam cell formation by reducing acetylated or oxidized low-density lipoprotein cholesterol uptake in diabetic subjects only. Conversely, deletion of the vitamin D receptor in macrophages from diabetic patients accelerated foam cell formation induced by modified LDL. 1,25(OH)(2)D(3) downregulation of c-Jun N-terminal kinase activation reduced peroxisome proliferated-activated receptor-gamma expression, suppressed CD36 expression, and prevented oxidized low-density lipoprotein-derived cholesterol uptake. In addition, 1,25(OH)(2)D(3) suppression of macrophage endoplasmic reticulum stress improved insulin signaling, downregulated SR-A1 expression, and prevented oxidized and acetylated low-density lipoprotein-derived cholesterol uptake. CONCLUSIONS: These results identify reduced vitamin D receptor signaling as a potential mechanism underlying increased foam cell formation and accelerated cardiovascular disease in diabetic subjects.
Anticancer Res. 2009 Sep; 29(9): 3647-58
Sertznig P, Dunlop T, Seifert M, Tilgen W, Reichrath J
The expression and signaling of the vitamin D receptor (VDR) and peroxisome proliferator-activated receptor (PPAR) alpha, delta, gamma was investigated in the melanoma cell line MeWo. Using real-time PCR, the mRNA of the nuclear receptors (NR) was detected. The strongest expression was found for the VDR, approximately 3-fold higher compared to the expression of PPARalpha or PPARdelta, and the weakest expression was for PPARgamma. After treatment with corresponding ligands, the expression of the VDR, PPARalpha and PPARdelta was elevated up to 5-fold, while the PPARgamma expression was not significantly affected. Treatment with 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitrol) resulted in 40% inhibition of MeWo cell proliferation, that was associated with a 5-fold increase in VDR mRNA. Interestingly, cell proliferation was differentially modulated by treatment with the PPAR ligands. While docosahexaenoic acid (DHA) treatment resulted in a statistically significant increase (approximately 10%), the other PPAR ligands inhibited MeWo cell proliferation. GW501516 (PPARdelta ligand) and WY14643 (PPARalpha ligand) both had an antiproliferative effect of approximately 10%. These antiproliferative effects were not associated with modulation of PPARalpha or PPARdelta expression. In contrast, stimulation of MeWo proliferation by DHA was associated with a 3- and 4-fold increase in the expression of PPARalpha and PPARdelta, respectively. Analyzing the cross-talk between the VDR and PPAR signaling pathways, the 1,25(OH)2D3 treatment resulted in an approximately 2-fold increase in expression of PPARalpha and PPARdelta, while the expression of PPARgamma was unaffected. Treatment with GW501516 and WY14643 resulted in an increase in the VDR expression (2-fold after 120 h). The simultaneous treatment with 1,25(OH)2D3 partially antagonised the DHA- and alpha-linolenicacid (ALA)-induced up-regulation of PPAR expression. In contrast, treatment with the PPAR ligands had no pronounced effect on the 1,25(OH)2D3-induced increase in VDR expression. Simultaneous treatment with the PPAR ligands bezafibrate or ALA resulted in an up to 6-fold reduction of the 1,25(OH)2D3-induced elevation of the 1alpha,25-dihydroxyvitamin D3-24-hydroxylase (CYP24A1) expression. Simultaneous treatment with the PPAR ligands and 1,25(OH)2D3 resulted in only marginal modulation of 1,25(OH)2D3-induced inhibition of cell proliferation. However, simultaneous treatment with bezafibrate and 1,25(OH)2D3 resulted in a statistically significant partial antagonisation of the 1,25(OH)2D3-induced inhibition of MeWo cell proliferation. In conclusion, PPAR and VDR have a role in growth regulation in melanoma cells and functionally relevant cross-talk between these nuclear signaling pathways is indicated, but not at the level of cell proliferation, where 1,25(OH)2D3 has a dominant effect.
J Biol Chem. 2009 Oct 2; 284(40): 27438-48
Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL
Loss of bone mass with advancing age in mice is because of decreased osteoblast number and is associated with increased oxidative stress and decreased canonical Wnt signaling. However, the underlying mechanisms are poorly understood. We report an age-related increase in the lipid oxidation product 4-hydroxynonenal (4-HNE) as well as increased expression of lipoxygenase and peroxisome proliferator-activated receptor-gamma (PPARgamma) in the murine skeleton. These changes together with decreased Wnt signaling are reproduced in 4-month-old mice bearing a high expressing allele of the lipoxygenase Alox15. The addition of 4-HNE to cultured osteoblastic cells increases oxidative stress, which in turn diverts beta-catenin from T-cell-specific transcription factors to Forkhead box O (FoxO) transcription factors, thereby attenuating the suppressive effect of beta-catenin on PPARgamma gene expression. Oxidized lipids, acting as ligands of PPARgamma, promote binding of PPARgamma2 to beta-catenin and reduce the levels of the latter, and they attenuate Wnt3a-stimulated proliferation and osteoblast differentiation. Furthermore, oxidized lipids and 4-HNE stimulate apoptosis of osteoblastic cells. In view of the role of oxidized lipids in atherogenesis, the adverse effects of lipoxygenase-mediated lipid oxidation on the differentiation and survival of osteoblasts may provide a mechanistic explanation for the link between atherosclerosis and osteoporosis.
Hop bitter acids efficiently block inflammation independent of GRalpha, PPARalpha, or PPARgamma.
Mol Nutr Food Res. 2009 Sep; 53(9): 1143-55
Van Cleemput M, Heyerick A, Libert C, Swerts K, Philippé J, De Keukeleire D, Haegeman G, De Bosscher K
Hop (Humulus lupulus L.) is an essential ingredient of beer, where it provides the typical bitter taste, but is also applied in traditional folk medicine for sedative and antibacterial purposes. In this study, we demonstrate and compare the anti-inflammatory effect of various classes of hop bitter acids (HBA), including alpha-acids (AA), beta-acids (BA), and iso-alpha-acids (IAA), in fibroblasts, which are important players in the inflammatory response. All three studied classes of HBA blocked the tumor necrosis factor alpha (TNF)-induced production of the cytokine IL6, and inhibited the transactivation of the pro-inflammatory transcription factors nuclear factor kappa B (NF-kappaB), activator protein-1 (AP-1), and cAMP-response element-binding protein (CREB). In this respect, the six-membered ring compounds AA and BA showed equal potency, whereas the five-membered ring compounds, IAA, were effective only when used at higher concentrations. Furthermore, with regard to the mechanism of NF-kappaB suppression, we excluded a possible role for glucocorticoid receptor alpha (GRalpha), peroxisome proliferators-activated receptor alpha/gamma (PPARalpha or PPARgamma), nuclear receptors (NRs) that are also known to inhibit inflammation by directly interfering with the activity of pro-inflammatory transcription factors. Interestingly, combining hop acids and selective agonists for GRalpha, PPARalpha, or PPARgamma resulted in additive inhibition of NF-kappaB activity after TNF treatment, which may open up new avenues for combinatorial anti-inflammatory strategies with fewer side effects. Finally, systemic administration of HBA efficiently inhibited acute local inflammation in vivo.